RFS Stock Overview
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Resverlogix Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.033 |
| 52 Week High | CA$0.11 |
| 52 Week Low | CA$0.033 |
| Beta | 0.72 |
| 1 Month Change | -9.72% |
| 3 Month Change | -17.72% |
| 1 Year Change | -70.72% |
| 3 Year Change | -94.49% |
| 5 Year Change | -98.78% |
| Change since IPO | -98.16% |
Recent News & Updates
Recent updates
Shareholder Returns
| RFS | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -4.3% | -2.5% |
| 1Y | -70.7% | -19.4% | -0.4% |
Return vs Industry: RFS underperformed the German Biotechs industry which returned -19.4% over the past year.
Return vs Market: RFS underperformed the German Market which returned -0.4% over the past year.
Price Volatility
| RFS volatility | |
|---|---|
| RFS Average Weekly Movement | 13.5% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: RFS's share price has been volatile over the past 3 months.
Volatility Over Time: RFS's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 19 | Don McCaffrey | www.resverlogix.com |
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications.
Resverlogix Corp. Fundamentals Summary
| RFS fundamental statistics | |
|---|---|
| Market cap | €10.30m |
| Earnings (TTM) | -€15.73m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs RFS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RFS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$16.74m |
| Earnings | -US$16.74m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.061 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -95.2% |
How did RFS perform over the long term?
See historical performance and comparison